Biocon shares rally nearly 6% after unit receives USFDA nod for cancer drug

April 11, 2025

Biocon’s shares surged following USFDA approval for Jobevne, a biosimilar to Avastin, used in treating various cancers. This marks Biocon’s seventh biosimilar approval in the U.S., strengthening its oncology portfolio. With bevacizumab sales reaching $2 billion in the U.S. in 2023, this approval signifies a major milestone for Biocon.

More To Explore

2 top stock recommendations from Amit Bhuptani

Currently, we are also seeing that the Fibonacci golden ratio is also coming near 24,400 level. So, closing once Nifty gets above that level on

May 6, 2025

Nifty up by 10% from April low. What should mutual fund investors do?

Nifty has surged 10% from its April low, reaching 24,461, prompting experts to advise caution on lumpsum investments due to expected volatility. SIPs remain the

May 6, 2025

Advertiser Disclosure

Great-investor.com helps users across the globe to find out The latest news, Guides, and Info about finance and investments. Furthermore, our content and research teams do not participate in any advertising planning nor are they permitted access to advertising campaign data.

Disclaimer

It is our organization’s primary mission to provide reviews, commentary, and analysis that are unbiased and objective. While great-investor.com has some data verified by industry participants, it can vary from time to time. Operating as an online business, this site may be compensated through third party advertisers. Our receipt of such compensation shall not be construed as an endorsement or recommendation by great-investor.com, nor shall it bias our reviews, analysis, and opinions. Please see our General Disclaimers for more information

Top10 International FZ LLE | 17th Floor, Creative Tower | 4422 | Fujairah | TRN: 100608946800003